2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2658

Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2125

Aggrecan Degradation Is Not Just Aggrecan Degradation:a Study of the Neo-Epitopes Tege and Args Released from Cartilage upon Aggrecanase Activity

Biology and Pathology of Bone and Joint - Poster I

9:00AM-11:00AM: Abstract Number: 2936

All-Trans Retinoic Acid Stabilizes Natural T Regulatory Cells Isolated from Patients with Systemic Lupus Erythematosus Under Inflammatory Conditions

T Cell Biology and Targets in Autoimmune Disease - Poster Session II

9:00AM-11:00AM: Abstract Number: 2160

Allopurinol Use and the Risk of Acute Cardiovascular Events in Patients with Gout and Diabetes

Epidemiology and Public Health - Poster III

9:00AM-11:00AM: Abstract Number: 2159

Allopurinol Use Is Associated with Lower Risk of Peripheral Vascular Disease in the US Elderly

Epidemiology and Public Health - Poster III

9:00AM-11:00AM: Abstract Number: 2267

AMP-Activated Protein Kinase: A Target for Methotrexate in Macrophages

Innate Immunity and Rheumatic Disease - Poster II

9:00AM-11:00AM: Abstract Number: 2851

An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2915

An Increased Circulating Level of Periostin in Patients with Systemic Sclerosis: Associations with Functional Impairment in Various Affected Organs

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2974

An Outcome Survey of 100 Patients with Cerebral Venous Sinus Thrombosis Due to Behcet’s Syndrome Followed up at a Single, Dedicated Center

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2186

Analgesic Use and Subsequent Risk of Falls in Participants with or at Risk of Knee Osteoarthritis

Epidemiology and Public Health - Poster III

9:00AM-11:00AM: Abstract Number: 2539

Analysis of Joints Susceptible to Rheumatoid Arthritis (RA) and Their Recovery Sequence Based on DAS28 and Physical Function Based on HAQ with Smart System of Disease Management (SSDM) in China：a Prospective Cohort Study

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2368

Analysis of Pain and Function Components in Omeract-Oarsi Strict Responders from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2383

Analysis of the Use of Anticoagulants and Antiplatelet Agents in Strokes Caused By the Deficiency of Adenosine Deaminase 2

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

9:00AM-11:00AM: Abstract Number: 2113

Anti-Carbamylated Protein Antibody (cross)-Reactivity Against Multiple Carbamylated Protein Antigens

B Cell Biology and Targets in Autoimmune Disease - Poster II: Rheumatoid Arthritis and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2608

Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].